Do analysts prefer ETHZ or SKYE?

Skye Bioscience has a consensus price target of $8.50, indicating a potential upside of 1,123.02%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than Flag Ship Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is ETHZ or SKYE more profitable?

Flag Ship Acquisition's return on equity of -185.71% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Flag Ship Acquisition N/A -185.71% -83.12% Skye Bioscience N/A -217.27% -162.39%

Does the media refer more to SKYE or VRCA?

In the previous week, Skye Bioscience and Skye Bioscience both had 2 articles in the media. Skye Bioscience's average media sentiment score of 0.94 equaled Verrica Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PMN or SKYE?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is PMN or SKYE more profitable?

Skye Bioscience's return on equity of -217.27% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Skye Bioscience N/A -217.27% -162.39%

Is RANI or SKYE more profitable?

Rani Therapeutics' return on equity of -206.46% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Skye Bioscience N/A -217.27% -162.39%

Does the media prefer RANI or SKYE?

In the previous week, Rani Therapeutics and Rani Therapeutics both had 2 articles in the media. Skye Bioscience's average media sentiment score of 0.94 beat Rani Therapeutics' score of 0.93 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SKYE or ATRA?

In the previous week, Skye Bioscience and Skye Bioscience both had 2 articles in the media. Skye Bioscience's average media sentiment score of 0.94 beat Atara Biotherapeutics' score of 0.93 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Skye Bioscience (SKYE) Competitors

$0.70 +0.02 (+3.65%)

As of 02:28 PM Eastern

Compare

SKYE vs. ETHZ, VRCA, PMN, RANI, and ATRA

Should you buy Skye Bioscience stock or one of its competitors? MarketBeat compares Skye Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Skye Bioscience include Flag Ship Acquisition (ETHZ), Verrica Pharmaceuticals (VRCA), Promis Neurosciences (PMN), Rani Therapeutics (RANI), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

How does Skye Bioscience compare to Flag Ship Acquisition?

Flag Ship Acquisition (NASDAQ:ETHZ) and Skye Bioscience (NASDAQ:SKYE) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Skye Bioscience has a consensus price target of $8.50, indicating a potential upside of 1,123.02%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than Flag Ship Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

4.1% of Flag Ship Acquisition shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 15.1% of Flag Ship Acquisition shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Flag Ship Acquisition has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.95, meaning that its stock price is 195% more volatile than the broader market.

Flag Ship Acquisition's return on equity of -185.71% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-185.71%	-83.12%
Skye Bioscience	N/A	-217.27%	-162.39%

Flag Ship Acquisition has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flag Ship Acquisition	$4.11M	26.74	-$6.17M	-$159.65	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

In the previous week, Skye Bioscience had 2 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 2 mentions for Skye Bioscience and 0 mentions for Flag Ship Acquisition. Skye Bioscience's average media sentiment score of 0.94 beat Flag Ship Acquisition's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Flag Ship Acquisition	Neutral
Skye Bioscience	Positive

Summary

Skye Bioscience beats Flag Ship Acquisition on 9 of the 15 factors compared between the two stocks.

How does Skye Bioscience compare to Verrica Pharmaceuticals?

Skye Bioscience (NASDAQ:SKYE) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, Skye Bioscience and Skye Bioscience both had 2 articles in the media. Skye Bioscience's average media sentiment score of 0.94 equaled Verrica Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Verrica Pharmaceuticals has higher revenue and earnings than Skye Bioscience. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Verrica Pharmaceuticals	$35.58M	3.01	-$17.89M	-$1.03	N/A

Skye Bioscience has a beta of 2.95, suggesting that its stock price is 195% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Skye Bioscience presently has a consensus price target of $8.50, suggesting a potential upside of 1,123.02%. Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 132.56%. Given Skye Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Skye Bioscience is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Skye Bioscience has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Skye Bioscience's return on equity of -217.27% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Summary

Skye Bioscience beats Verrica Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Skye Bioscience compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Promis Neurosciences currently has a consensus price target of $26.50, suggesting a potential upside of 107.92%. Skye Bioscience has a consensus price target of $8.50, suggesting a potential upside of 1,123.02%. Given Skye Bioscience's higher possible upside, analysts clearly believe Skye Bioscience is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Skye Bioscience's return on equity of -217.27% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Skye Bioscience	N/A	-217.27%	-162.39%

In the previous week, Promis Neurosciences and Promis Neurosciences both had 2 articles in the media. Promis Neurosciences' average media sentiment score of 0.94 equaled Skye Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Promis Neurosciences	Positive
Skye Bioscience	Positive

Promis Neurosciences is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Promis Neurosciences has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.95, suggesting that its share price is 195% more volatile than the broader market.

Summary

Skye Bioscience beats Promis Neurosciences on 6 of the 11 factors compared between the two stocks.

How does Skye Bioscience compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 1,048.29%. Skye Bioscience has a consensus target price of $8.50, suggesting a potential upside of 1,123.02%. Given Skye Bioscience's higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Rani Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Rani Therapeutics and Rani Therapeutics both had 2 articles in the media. Skye Bioscience's average media sentiment score of 0.94 beat Rani Therapeutics' score of 0.93 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics' return on equity of -206.46% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Skye Bioscience	N/A	-217.27%	-162.39%

Rani Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.95, meaning that its share price is 195% more volatile than the broader market.

Rani Therapeutics has higher revenue and earnings than Skye Bioscience. Rani Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$3.17M	29.79	-$29.67M	-$0.41	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Summary

Rani Therapeutics beats Skye Bioscience on 9 of the 14 factors compared between the two stocks.

How does Skye Bioscience compare to Atara Biotherapeutics?

Skye Bioscience (NASDAQ:SKYE) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Skye Bioscience and Skye Bioscience both had 2 articles in the media. Skye Bioscience's average media sentiment score of 0.94 beat Atara Biotherapeutics' score of 0.93 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Skye Bioscience has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Atara Biotherapeutics has higher revenue and earnings than Skye Bioscience. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Atara Biotherapeutics	$120.77M	0.86	$32.69M	-$0.67	N/A

Skye Bioscience currently has a consensus target price of $8.50, suggesting a potential upside of 1,123.02%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential downside of 17.89%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Skye Bioscience is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Skye Bioscience has a beta of 2.95, indicating that its stock price is 195% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Summary

Skye Bioscience beats Atara Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get Skye Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYE vs. The Competition

Export

Metric	Skye Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.42M	$3.65B	$6.78B	$12.58B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	-0.48	21.25	27.32	24.86
Price / Sales	N/A	340.58	561.22	117.20
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	1.12	8.81	11.08	6.58
Net Income	-$55.92M	$23.81M	$3.57B	$336.70M
7 Day Performance	-0.71%	4.01%	2.62%	3.29%
1 Month Performance	-10.37%	1.98%	0.95%	1.72%
1 Year Performance	-83.37%	70.53%	37.04%	31.91%

Skye Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYE Skye Bioscience	2.1295 of 5 stars	$0.70 +3.7%	$8.50 +1,123.0%	-83.7%	$24.42M	N/A	N/A	11	News Coverage
ETHZ Flag Ship Acquisition	N/A	$5.16 +2.2%	N/A	N/A	$98.10M	$4.11M	N/A	7
VRCA Verrica Pharmaceuticals	3.002 of 5 stars	$5.65 +0.2%	$14.50 +156.6%	+24.4%	$96.89M	$35.58M	N/A	40
PMN Promis Neurosciences	3.7432 of 5 stars	$10.69 +0.1%	$26.50 +147.9%	-10.5%	$95.78M	N/A	N/A	5	News Coverage Analyst Forecast Gap Up
RANI Rani Therapeutics	2.3482 of 5 stars	$0.76 -2.3%	$8.75 +1,058.9%	+38.5%	$95.72M	$1.63M	N/A	110	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYE) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Skye Bioscience (SKYE) Competitors

SKYE vs. ETHZ, VRCA, PMN, RANI, and ATRA

How does Skye Bioscience compare to Flag Ship Acquisition?

Summary

How does Skye Bioscience compare to Verrica Pharmaceuticals?

Summary

How does Skye Bioscience compare to Promis Neurosciences?

Summary

How does Skye Bioscience compare to Rani Therapeutics?

Summary

How does Skye Bioscience compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Skye Bioscience (SKYE) Competitors

SKYE vs. ETHZ, VRCA, PMN, RANI, and ATRA

How does Skye Bioscience compare to Flag Ship Acquisition?

Do analysts prefer ETHZ or SKYE?

Do institutionals & insiders believe in ETHZ or SKYE?

Which has more risk & volatility, ETHZ or SKYE?

Is ETHZ or SKYE more profitable?

Which has higher valuation & earnings, ETHZ or SKYE?

Does the media favor ETHZ or SKYE?

Summary

How does Skye Bioscience compare to Verrica Pharmaceuticals?

Does the media refer more to SKYE or VRCA?

Do institutionals and insiders hold more shares of SKYE or VRCA?

Which has better valuation and earnings, SKYE or VRCA?

Which has more risk & volatility, SKYE or VRCA?

Do analysts recommend SKYE or VRCA?

Is SKYE or VRCA more profitable?

Summary

How does Skye Bioscience compare to Promis Neurosciences?

Do analysts rate PMN or SKYE?

Is PMN or SKYE more profitable?

Does the media prefer PMN or SKYE?

Which has stronger earnings and valuation, PMN or SKYE?

Do institutionals and insiders have more ownership in PMN or SKYE?

Which has more risk and volatility, PMN or SKYE?

Summary

How does Skye Bioscience compare to Rani Therapeutics?

Do institutionals and insiders hold more shares of RANI or SKYE?

Do analysts prefer RANI or SKYE?

Does the media prefer RANI or SKYE?

Is RANI or SKYE more profitable?

Which has more volatility and risk, RANI or SKYE?

Which has higher earnings & valuation, RANI or SKYE?

Summary

How does Skye Bioscience compare to Atara Biotherapeutics?

Does the media refer more to SKYE or ATRA?

Is SKYE or ATRA more profitable?

Which has stronger valuation & earnings, SKYE or ATRA?

Do analysts rate SKYE or ATRA?

Do institutionals and insiders have more ownership in SKYE or ATRA?

Which has more volatility and risk, SKYE or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools